Abrial C et al. Aromatase inhibitors and metastatic breast cancer survival. Proc ASCO 2005;Abstract 767.

Bundred N. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer. Cancer Invest 2005;23(2):173-81. Abstract

Buzdar AU. Hormonal therapy in early and advanced breast cancer. Breast J 2004;10(Suppl 1):19-21. Abstract

Buzdar AU et al. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: A review of data from first-line metastatic disease trials in postmenopausal women. Breast J 2004;10(3):211- 7. Abstract

Cameron DA et al. A comparative study of exemestane versus anastrozole in postmenopausal breast cancer subjects with visceral disease. Proc ASCO 2004;Abstract 628.

Cardoso AA et al. Fulvestrant after aromatase inhibitor failure: Results from the expanded access program in Rio de Janeiro, Brazil. Breast Cancer Res Treat 2004;Abstract 6050.

Carlini P et al. New aromatase inhibitors (Als) as first-line endocrine therapy (ET) in metastatic breast cancer (MBC): A pooled analysis of 3238 women from 8 phase III trials. Proc ASCO 2005;Abstract 602.

Carlson RW et al. Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/ metastatic breast cancer. Breast Cancer Res Treat 2004;Abstract 6052.

Cheung K et al. Goserelin plus anastrozole as first-line endocrine therapy for premenopausal women with oestrogen receptor (ER) positive advanced breast cancer (ABC). Proc ASCO 2005;Abstract 731.

Come SE, Borges VF. Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women. Clin Breast Cancer 2005;6 Suppl 1:S15-22. Abstract

Dixon JM. Exemestane and aromatase inhibitors in the management of advanced breast cancer. Expert Opin Pharmacother 2004;5(2):307-16. Abstract

Dodwell D, Vergote I. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rev 2005;31(4):274-82. Abstract

Dodwell D, Vergote I. Fulvestrant: A new, effective and well-tolerated second-line treatment option for postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 2004;Abstract 6051.

Dowsett M et al. Biological characteristics of the pure antiestrogen fulvestrant: Overcoming endocrine resistance. Breast Cancer Res Treat 2005;93(Suppl 4):11-8. Abstract

Ferrari L et al. Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? Int J Oncol 2003;22(5):1081-9. Abstract

Forward DP et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90(3):590-4. Abstract

Franco S et al. Response to fulvestrant in heavily pretreated postmenopausal women: A single-center experience. Breast Cancer Res Treat 2004;88(2):103-8. Abstract

Gradishar W. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer. Expert Rev Anticancer Ther 2005;5(3):445- 53. Abstract

Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005;89(Suppl 1):9-15. Abstract

Gutteridge E et al. Effects of fulvestrant on estrogen receptor levels during long-term treatment of patients with advanced breast cancer — final results. Breast Cancer Res Treat 2004;Abstract 4086.

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

Howell A et al. A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Breast Cancer Res Treat 2003;82(3):215-22. Abstract

Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract

Iaffaioli RV et al. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer 2005;92(9):1621-5. Abstract

Iaffaioli RV et al. Preliminary data of GOIM 2107 study: Multicenter phase II study of sequential hormonotherapy with anastrozole/ exemestane in metastatic breast disease. Proc ASCO 2004;Abstract 820.

Ingle JN et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: A phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat 2004;Abstract 409.

Ingle JN. Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clin Cancer Res 2004;10(1 Pt 2):362-7. Abstract

Ingle JN, Suman VJ. Aromatase inhibitors for therapy of advanced breast cancer. J Steroid Biochem Mol Biol 2005;95(1-5):113-9. Abstract

Irish W et al. Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. Ann Oncol 2005;16(9):1458-62. Abstract

Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 2004;90(Suppl 1):15-8. Abstract

Johnston SR et al. Life following aromatase inhibitors - where now for endocrine sequencing? Breast Cancer Res Treat 2005;93 Suppl 4:19-25. Abstract

Jones SE, Pippen J. Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 2005;6(Suppl)1:9-14. Abstract

Jones SE et al. A retrospective analysis of the proportion of patients responding for > 1 year in two phase III studies of fulvestrant vs anastrozole. Proc ASCO 2004;Abstract 737.

Jones SE et al. A retrospective analysis of the proportion of patients responding for ≥ 1, 1.5 and 2 years in two phase III studies of fulvestrant vs anastrozole. Breast Cancer Res Treat 2004;Abstract 6047.

Kaufmann M et al. Exemestane improves survival in metastatic breast cancer: Results of a phase III randomized study. Clin Breast Cancer 2000;(1 Suppl 1):15-8. Abstract

Marcom PK et al. A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: Final results. Proc ASCO 2005;Abstract 596.

Mauriac L et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and nonvisceral metastases: Combined results from two multicentre trials. Eur J Cancer 2003;39(9):1228-33. Abstract

McKeage K et al. Fulvestrant: A review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Drugs 2004;64(6):633-48. Abstract

Milla-Santos A et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, phase III study. Am J Clin Oncol 2003;26(3):317-22. Abstract

Mouridsen H, Chaudri-Ross HA. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. Oncologist 2004;9(5):497-506. Abstract

Mouridsen H et al. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: Evidence from metastatic subgroups and a test of functional ability. Oncologist 2004;9(5):489-96. Abstract

Mouridsen H et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21(11):2101-9. Abstract

Nabholtz JM et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Survival analysis and updated safety results. Eur J Cancer 2003;39(12):1684-9. Abstract

Osborne CK et al. Fulvestrant: An oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 2004;90(Suppl 1):2-6. Abstract

Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract

Paridaens R et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) — A randomized phase III trial of the EORTC Breast Group. Proc ASCO 2004;Abstract 515.

Perey L et al. Fulvestrant (Faslodex) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: Update of a phase II SAKK trial. Breast Cancer Res Treat 2004;Abstract 6048.

Petruzelka L et al. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy — Results from a compassionate use program. Proc ASCO 2004;Abstract 730.

Possinger K. Fulvestrant — A new treatment for postmenopausal women with hormone-sensitive advanced breast cancer. Expert Opin Pharmacother 2004;5(12):2549-58. Abstract

Pritchard KI. Endocrine therapy of advanced disease: Analysis and implications of the existing data. Clin Cancer Res 2003;9(1 Pt 2):460- 7. Abstract

Prowell TM, Davidson NE. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Oncologist 2004;9(5):507-17. Abstract

Rivera E et al. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clin Cancer Res 2004;10(6):1943-8. Abstract

Robertson JF et al. Endocrine treatment options for advanced breast cancer — The role of fulvestrant. Eur J Cancer 2005;41(3):346-56. Abstract

Robertson JF et al. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005;92(2):169-74. Abstract

Robertson JFR et al. Clinical efficacy of fulvestrant and effects on estrogen receptor levels during first-line endocrine treatment of patients with advanced breast cancer. Breast Cancer Res Treat 2004;Abstract 6049.

Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract

Sokolowicz LE, Gradishar WJ. Implications of first-line adjuvant treatment with aromatase inhibitors in recurrent metastatic breast cancer. Clin Breast Cancer 2004(5 Suppl 1):24-30. Abstract

Steger G et al. Fulvestrant (FUL) and goserelin (GOS) in premenopausal women with advanced, hormone-sensitive breast cancer — A pilot study. Proc ASCO 2005;Abstract 708.

Steger GG et al. Fulvestrant (‘Faslodex’): Clinical experience from the Compassionate Use Programme. Cancer Treat Rev 2005;31 Suppl 2: S10-6. Abstract

Thürlimann B et al. Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 — a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004;85(3):247-54. Abstract

Thürlimann B et al; Arimidex Study Group. Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003;39(16):2310-7. Abstract

Traina TA et al. A feasibility study of an aromatase inhibitor (AI), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizumab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). Proc ASCO 2005;Abstract 796.

Vergote I, Robertson JF. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: Results from clinical trials. Br J Cancer 2004;90(Suppl 1):11-4. Abstract

Vergote I et al; Trial 0020 Investigators. Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79(2):207-11. Abstract

Vogel CL. Update on the current use of hormonals as therapy in advanced breast cancer. Anticancer Drugs 2003;14(4):265-73. Abstract